GlassScriptPhysician profile
Christopher L Willingham
NPI 1225096183
$30,105.40
in general payments reported to CMS, 2019-2025
16 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,021 · 2020: $2,993 · 2021: $12K · 2022: $9,645 · 2023: $354 · 2024: $525 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,284.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $28,153.53 | 2019-2022 | |
| Abbvie INC. | $539.70 | 2022-2025 | Ozurdex |
| Regeneron Healthcare Solutions, INC. | $437.71 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $253.36 | 2020-2024 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $111.44 | 2019 | |
| Apellis Pharmaceuticals, INC. | $108.85 | 2023-2024 | Syfovre |
| Astellas Pharma US INC | $103.89 | 2023-2025 | Izervay |
| Allergan, INC. | $96.29 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $85.54 | 2022-2024 | Xipere |
| Biogen, INC. | $68.62 | 2022-2024 | Byooviz |
| Coherus Oncology, INC. | $44.07 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $24.58 | 2024 | Acthar |
| Harrow Eye, LLC | $22.47 | 2025 | Triesence |
| Ani Pharmaceuticals, INC. | $21.61 | 2025 | Iluvien |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $14.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$780,218.40 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Willingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.